Archive · 23 Sep 2025
US Tariffs and Regulations Impact Sun Pharma Business
Sun Pharma, an Indian drug company, is dealing with potential problems in the US market.
The US government might put tariffs (extra taxes) on Indian goods, which could hurt Sun Pharma's business.
The company's specialty medicines are doing well, particularly in areas like skin treatments.
However, a key manufacturing plant failed an inspection, and the company’s stock price has fallen.
Also, their tax rate will increase, and profits are expected to grow more slowly in the coming year.
Despite this, they are preparing to launch new drugs in India.
Sun Pharma faces potential impact from US tariffs on Indian imports.
The US market contributes significantly to Sun Pharma's revenue, mainly from specialty products.
The specialty business, including dermatology and oncodermatology products, is growing rapidly.
A key launch, Leqselvi, used for severe alopecia areata, has been well-received.
Sun Pharma's shares have fallen in 2025 due to uncertainties including tariff implications and regulatory issues.
- Who
- Sun Pharmaceutical Industries Ltd.
- What
- Faces uncertainty due to US tariffs and regulatory issues affecting its business.
- When
- FY26 earnings are expected to grow slower.
- Where
- US market, India, and Sun Pharma’s manufacturing plants.
- Why
- Due to potential US tariffs, tax changes, and regulatory inspections.
- FY25 Revenue (US Market)
- 31% of ₹52,000 crore
- Specialty Business CAGR (FY21-25)
- 26%
- Specialty Revenue of Total Revenue (FY25)
- 20%
- Shares Decline in 2025
- Over 13%
- FY26 EPS Growth
- 6.3% (estimated)